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Increases in adiposity trigger metabolic and inflam-
matory changes that interfere with insulin action in
peripheral tissues, culminating in beta cell failure
and overt diabetes. We found that the cAMP
Response Element Binding protein (CREB) is acti-
vated in adipose cells under obese conditions, where
it promotes insulin resistance by triggering expres-
sion of the transcriptional repressor ATF3 and
thereby downregulating expression of the adipokine
hormone adiponectin as well as the insulin-sensitive
glucose transporter 4 (GLUT4). Transgenic mice ex-
pressing a dominant-negative CREB transgene in
adipocytes displayed increased whole-body insulin
sensitivity in the contexts of diet-induced and
genetic obesity, and they were protected from the
development of hepatic steatosis and adipose tissue
inflammation. These results indicate that adipocyte
CREB provides an early signal in the progression to
type 2 diabetes.
INTRODUCTION
During fasting, mammals maintain energy balance by shifting
from glucose to fat burning. Circulating catecholamines mobilize
triglyceride stores fromwhite adipose tissue (WAT) by increasing
lipolysis (Joost et al., 1986, 1988; Laakso et al., 1992) and by
reducing glucose uptake in fat through activation of the cAMP
pathway (Joost et al., 1986, 1988; Laakso et al., 1992). Although
they decrease membrane targeting of the GLUT4 transporter,
catecholamines also downregulate adipocyte GLUT4 gene
expression in adipose in response to fasting and type 2 diabetes
(Berger et al., 1989; Garvey et al., 1989; Kahn et al., 1989; Sivitz
et al., 1989).
Superimposed on these metabolic effects, catecholamines
also inhibit the expression and secretion of certain adipocytokine
hormones, most notably adiponectin, a key modulator of
systemic insulin sensitivity (Delporte et al., 2002; Fu et al.,
2007; Ricci et al., 2005; Scriba et al., 2000). Depletion of adipo-Cenectin in adipose reduces insulin sensitivity (Kubota et al., 2002;
Maeda et al., 2002; Nawrocki et al., 2006) while overexpression
of adiponectin enhances it, in part through effects on hepatic
glucose production (HGP) (Berg et al., 2001; Combs et al.,
2001; Kim et al., 2007; Satoh et al., 2005; Yamauchi et al.,
2002b).
The CREB family of cAMP-responsive transcription factors
(CREB1, CREM, ATF1) has been found to mediate effects of
catecholamines and other fasting hormones on cellular gene
expression (Herzig et al., 2001; Zhang et al., 2005a). Following
its phosphorylation at Ser133, CREB stimulates transcription
through recruitment of the histone acetylase CBP and through
an association with the CREB Regulated Transcriptional Coacti-
vator (CRTC, also known as TORC2) family of latent cytoplasmic
coactivators (Chrivia et al., 1993; Ravnskjaer et al., 2007; Xu
et al., 2007). CREB promotes glucose homeostasis during fast-
ing, for example, by triggering expression of the gluconeogenic
program in liver (Herzig et al., 2001). Hepatic CREB activity is
constitutively upregulated in diabetes, where it contributes to
hyperglycemia and insulin resistance (Dentin et al., 2007,
2008). The extent to which adiponectin or other adipose-derived
hormonesmodulate hepatic gluconeogenesis via CREB remains
unclear, however.
In addition to its function in liver, CREB also appears to
promote expression of the adipogenic program in preadipocytes
(Zhang et al., 2004), although its role in mediating effects of
cAMP in mature adipocytes has not been addressed. We found
that adipocyte CREB is activated in obesity, when it disrupts
insulin action and promotes systemic insulin resistance. Block-
ing CREB activity in adipocytes prevented the development of
inflammatory infiltrates in adipose as well as systemic insulin
resistance under obese conditions. These results point to
a central role for adipose tissue in coordinating systemic insulin
action and in modulating energy balance in part through obesity-
related increases in CREB activity.
RESULTS
Insulin Sensitivity in Obese Mice with Reduced
Adipocyte CREB Activity
CREB family members (CREB1, CREM, ATF1) exhibit consider-
able functional redundancy (Mayr andMontminy, 2001; Shaywitzll Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc. 277
Cell Metabolism
Role of CREB in Obesityand Greenberg, 1999), and mice with individual knockouts show
only limited phenotypes (Bleckmann et al., 2002; Blendy et al.,
1996; Hummler et al., 1994). To block the activity of all CREB
family members in mature adipocytes, we generated transgenic
mice that express the dominant-negative CREB inhibitor
ACREB, a synthetic polypeptide that heterodimerizes with and
disrupts binding of CREB1, CREM, and ATF1 but not unrelated
bZIP proteins to DNA (Ahn et al., 1998). Because CREB has
been found to promote adipogenesis (Tseng et al., 2005; Zhang
et al., 2004), we targeted ACREB expression specifically to
mature adipocytes using the adipose-specific aP2 promoter.
ACREB mRNA was detected in adipocytes but not in perito-
neal macrophages or in adipose-derived stromal vascular cells
from two independent FAT-ACREB (F-ACREB) founder lines es-
tablished on different genetic backgrounds (CB6 and C57/Bl6)
(Figures 1A and S1). Expression of ACREB, either acutely by
adenoviral delivery or chronically in cells from F-ACREB trans-
genic mice, reduced mRNA amounts for the CREB target gene
NR4A2 in primary adipocyte cultures exposed to the cAMP acti-
vator forskolin (FSK) (Figure 1B). F-ACREB mice grow normally
and are indistinguishable from control littermates under normal
chow (NC) conditions (Figure S2).
In the insulin-resistant state, chronic elevations in circulating
insulin paradoxically potentiate catecholamine effects on
cAMP signaling in adipocytes (Hupfeld et al., 2003; Zhang
Figure 1. Mice Deficient in Adipocyte CREB
Activity Remain Insulin Sensitive under Obese
Conditions
(A) Top shows schematic of dominant-negative
ACREB transgene expressed from the fat-specific
aP2 promoter in FAT-ACREB (F-ACREB) C57/Bl6
mice. Bottom shows Q-PCR analysis of ACREB
mRNA amounts in peritoneal macrophages (MF) and
adipocytes from wild-type (WT) or transgenic (tg)
F-ACREB littermates.
(B) Top, immunoblot showing relative amounts of
phospho (Ser133) CREB (P-CREB) in adipose from
mice maintained on normal chow (NC) or high-fat
diet (HFD). Right shows relative P-CREB amounts in
adipose from lean or genetically obese (db) mice.
Bottom shows effect of forskolin (FSK) exposure
(4 hr) on CREB target gene expression (NR4A2) in
cultured adipocytes expressing ACREB through
adenoviral infection (ob Ad-ACREB) or chronically in
cells from F-ACREB transgenic (tg ob) mice.
(C and D) Relative circulating blood glucose concen-
trations in control (WT) and F-ACREB (tg) mice under
HFD (C) and genetically obese conditions (ob/ob) (D;
WT ob and tg ob). Glucose levels were evaluated in
overnight-fasted and 2 hr-refed mice.
(E and F) Glucose (E) and insulin (F) tolerance testing of
F-ACREB mice relative to WT littermates maintained
under HFD conditions for 9.5 weeks. Unless stated
otherwise, mice were maintained on HFD for 8–12
weeks, while ob/ob mice were analyzed at 12–16
weeks of age (*; p < 0.05). Data are means ± SEM.
et al., 2005a). Indeed, amounts of Ser133-
phosphorylated, active CREB were
increased following high-fat diet (HFD)
feeding and in genetically obese (db/db)
mice relative to lean controls (Figure 1B). To determine the
consequence of CREB activation in this setting, we performed
metabolic studies on F-ACREB mice following HFD feeding or
after breeding them onto a genetically obese (ob/ob) back-
ground. Compared to controls, F-ACREB mice had lower circu-
lating blood glucose concentrations despite similar food intake,
body temperature, physical activity, weight gain, and fat mass in
each group (Figures 1C, 1D, and S3). Whole-body insulin sensi-
tivity was also improved in F-ACREB animals after 9.5 weeks of
HFD feeding, as revealed by glucose (GTT) and insulin (ITT) toler-
ance testing (Figures 1E and 1F).
Systemic Insulin Sensitivity in F-ACREB Mice
To determine the relative effects of adipose-specific ACREB
expression on insulin resistance in muscle and liver, we per-
formed euglycemic-hyperinsulinemic clamp studies. After 24
weeks of HFD feeding, basal glucose infusion rates (GIR) during
the clamp studies were elevated 5-fold in F-ACREBmice relative
to controls, and insulin-stimulated glucose disposal rates (IS-
GDR), measures of muscle insulin sensitivity, were increased
10-fold (Figures 2A–2C). Adipose-specific expression of ACREB
caused similar changes in liver, where insulin infusion during the
clamp study inhibited HGP 3-fold greater in transgenic
compared to wild-type (WT) littermates (Figure 2D). Consistent
with an increase in insulin signaling, amounts of phosphorylated,278 Cell Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc.
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liver from F-ACREB animals following insulin injection (Figures
2E, 2F, and S4).
Despite the elevations in circulating glucose levels in the
control group, plasma insulin concentrations were comparable
between transgenic and control littermates (Figure S5), suggest-
ing an increased efficiency of glucose-stimulated insulin release
in F-ACREB animals. To test this idea, we monitored circulating
insulin concentrations under hyperglycemic clamp conditions. In
line with their relative insulin sensitivity, GIR were increased 75%
in HFD-fed transgenic mice compared to controls (Figure S6).
Pointing to an overall improvement in pancreatic islet function,
circulating insulin levels rose substantially in glucose-stimulated
F-ACREB mice but not in control animals. Taken together, these
results indicate that the adipose-specific disruption of CREB
activity prevents the development of beta cell failure in the
context of obesity.
White adipose stores from obese individuals are often charac-
terized by immune cell infiltrates that further aggravate insulin
resistance through the release of inflammatory chemokines
Figure 2. Adipose-Specific Disruption of CREB Activity Enhances
Insulin Sensitivity in Muscle and Liver
(A–F) Euglycemic-hyperinsulinemic clamp studies of WT (n = 8) and F-ACREB
(n = 9) mice that were maintained on a HFD for 24 weeks. In (A), blood glucose
concentrations in HFD-fed F-ACREB (tg) and WT littermates prior to (basal) or
after euglycemic clamping (clamp) are shown. Also shown are basal glucose
infusion rates (GIRs) (B) and insulin-stimulated glucose disposal rates (IS-
GDR) (C) in F-ACREB and control mice under HFD conditions (**; p <
0.00001). In (D), relative inhibition of hepatic glucose production (HGP) by
insulin in F-ACREB and control mice is shown (*; p < 0.003). Also shown are
immunoblots of phospho-AKT and total AKT protein amounts in skeletal
muscle (E) and liver (F) lysates from F-ACREB and control littermates following
insulin injection. Data are means ± SEM.(Weisberg et al., 2003; Xu et al., 2003). Although they were abun-
dant in fat pads from HFD-fed controls, immune cells were rela-
tively absent in WAT from F-ACREB mice (Figure 3A). As well,
inflammatory pathway gene expression was substantially
reduced in WAT from HFD-fed F-ACREB mice compared to
WT (Figure S7). Consistent with these improvements, insulin-
stimulated glucose uptake was increased in adipocytes from
HFD-fed F-ACREBmice (Figure 3B). mRNA and protein amounts
for the insulin-sensitive GLUT4 transporter were also elevated.
Enhanced Adiponectin Expression in F-ACREB Mice
We considered that ACREB expression in adipocytes may
improve systemic insulin sensitivity in F-ACREB mice by altering
the profile of circulating adipocytokine hormones. Although
plasma concentrations of resistin, RBP4, tumor necrosis factor
(TNF)-a, and IL-1bwere similar in both groups (Figure S8), circu-
lating levels of high molecular weight, active adiponectin protein
were elevated in F-ACREB transgenic compared toWT controls;
adiponectin mRNA amounts in F-ACREB WAT were also
increased (Figures 3C and S9). Adiponectin has been found to
enhance insulin signaling in liver and other tissues through induc-
tion of the Ser/Thr kinase AMPK (Nawrocki et al., 2006; Ruder-
man et al., 2003; Yamauchi et al., 2002a). Supporting this notion,
amounts of phosphorylated, active AMPK were upregulated in
livers from F-ACREBmice compared to controls (Figure 3D, top).
AMPK is thought to improve hepatic insulin sensitivity in part
by preventing the abnormal accumulation of triglycerides,
a condition known as hepatic steatosis. Indeed, large lipid drop-
lets were evident in livers from ob/ob controls, but they were
relatively scarce in F-ACREB ob/ob mice (Figure 3D, bottom).
Consistent with these changes, hepatic ketone levels and
fatty-acid oxidation gene expression were elevated, while lipo-
genic gene expression was decreased in F-ACREB ob/ob
animals compared to controls (Figures 3E, 3F, and S10).
Superimposed on its role in hepatic lipid metabolism, AMPK
also reducesglucoseproductionby the liver in part throughphos-
phorylation of the CREB coactivator CRTC2 (Foretz et al., 1998;
Lochheadet al., 2000;Kooet al., 2005;Shawet al., 2005). Indeed,
amounts of phosphorylated, inactive CRTC2 were increased in
livers from F-ACREB mice, while mRNA amounts for gluconeo-
genic genes were reduced (Figures 3D, 3F, and S10).
Adiponectin Inhibits CRTC2 Activity
Having seen that hepatic CRTC2 activity is curtailed in F-ACREB
animals, we wondered whether adiponectin directly modulates
the gluconeogenic program via AMPK-mediated phosphoryla-
tion and inactivation of CRTC2. Exposure of cultured primary
hepatocytes to FSK triggered CRTC2 dephosphorylation,
leading to increases in cAMP response element (CRE)-luciferase
reporter activation, gluconeogenic gene expression, and
glucose production (Figures 4A–4D). Demonstrating the impor-
tance of CRTC2 dephosphorylation, CRE-luciferase activity
and glucose output were constitutively elevated in cells express-
ing phosphorylation-defective, active S171A CRTC2.
Based on the ability for adiponectin (Ad-adiponectin) to lower
glucose production following adenoviral delivery into liver (Satoh
et al., 2004, 2005), we examined effects of Ad-adiponectin
expression in primary hepatocytes on CRTC2 activity. Indeed,
Ad-adiponectin blocked the dephosphorylation of CRTC2 andCell Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc. 279
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mation and Hepatic Steatosis in F-ACREB
Mice
(A) Histological analysis of H&E-stained WAT
sections from HFD-fed F-ACREB (tg) and control
(WT) littermates showing relative accumulation of
inflammatory cell infiltrates.
(B) Top, insulin-stimulated glucose uptake in
primary cultured adipocytes from F-ACREB trans-
genic (tg HFD) and control (WT HFD) littermates
under HFD conditions. Relative uptake of [3H]2-
deoxyglucose (4 mCi/ml; expressed as counts
per minute/106 cells) into cultured adipocytes
fromHFD-fedmice exposed to various concentra-
tions of insulin for 20 min followed by incubation
with [3H]2-deoxyglucose for 5 min is shown (*;
p < 0.002 relative to WT HFD-fed mice; data are
means ± SEM). Bottom shows immunoblot of
GLUT4 protein amounts in adipose and quadri-
ceps muscle from F-ACREB (Tg1, Tg2) and WT
(WT1, WT2) littermates maintained under HFD
conditions.
(C) Top, Q-PCR analysis of adiponectin mRNA
amounts in adipose tissue from F-ACREB (tg
HFD) and WT (WT HFD) littermates maintained
under HFD conditions (n = 3 per group; *; p <
0.05); bottom, circulating plasma adiponectin
concentrations in fasted or 2 hr-refed F-ACREB
and control mice.
(D) Top, immunoblot showing phospho-AMPK
amounts in liver lysates from WT, ob/ob (WT-ob),
and F-ACREB transgenic (tg-ob) mice. Amounts
of unphospho- and phospho-CRTC2 are also indi-
cated. Bottom shows hepatic sections from F-
ACREB transgenic ob/ob and control ob/ob mice
showing relative accumulation of lipid droplets.
(E) Acetoacetate content in livers of F-ACREB ob/
ob and control ob/ob mice relative to lean WT
animals (n = 4). (*; p < 0.05 transgenic relative to
control mice; n = 4; data are means ± SEM.)
(F) Q-PCR analysis of beta oxidation (PGC-1a,
PPARa, UCP2) and gluconeogenic (PEPCK,
G6Pase) gene expression in livers from ob/ob
F-ACREB transgenic mice relative to ob/ob
controls.correspondingly lowered CRE-luciferase reporter activation in
cells exposed to FSK (Figures 4A–4D). As a result, adiponectin
also downregulated gluconeogenic gene expression (G6Pase,
PEPCK) and glucose production. But Ad-adiponectin did not
reduce CRE-luciferase activity or glucose output in hepatocytes
expressing the phosphorylation-defective S171A CRTC2, con-
firming the importance of Ser171 phosphorylation for these
effects. Indeed, exposure of primary mouse hepatocytes to
physiologic concentrations of adiponectin (2–15 mg/ml) (Kado-
waki et al., 2006) also blocked CRTC2 dephosphorylation and
CRE-luciferase reporter activation in cells exposed to FSK
(Figures 4E and 4F). Taken together, these results support the
notion that adiponectin reduces hepatic gluconeogenesis via
the AMPK-mediated phosphorylation of CRTC2 at Ser171.
CREB Stimulates ATF3 Expression in Obesity
Having seen that GLUT4 and adiponectin gene expression in
WAT is relatively higher in obese F-ACREB mice over controls,280 Cell Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc.we considered that CREB could inhibit these genes directly or
through upregulation of a transcriptional repressor. Arguing
against a direct effect, CREB binding over the adiponectin and
GLUT4 promoters was not detectable by chromatin immunopre-
cipitation assay (Zhang et al., 2005b; data not shown). In gene-
profiling assays to characterize putative CREB target genes
that are upregulated 2-fold or better in primary adipocytes
exposed to FSK and in WAT from HFD-fed compared to NC-
fed mice, we identified the transcriptional repressor ATF3
(Chen et al., 1994) as the top-scoring gene (Figure 5A). ATF3
mRNA and protein amounts were increased nearly 10-fold in
WAT from HFD-fed and genetically obese ob/ob mice relative
to lean controls (Figure 5B, top). Conversely, ATF3 protein and
mRNA amounts were decreased in WAT from F-ACREB mice
compared to WT littermates (Figure 5B, bottom).
Realizing that the ATF3 promoter contains a conserved CRE in
the proximal promoter (Liang et al., 1996), we tested the role of
CREB in modulating this gene directly in adipocytes. Exposure
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increased ATF3 mRNA amounts; these effects were blocked
following expression of adenovirally encoded ACREB
(Figure 5C). ATF3 mRNA amounts—elevated in primary adipo-
cytes from ob/ob mice—were downregulated in cells from
F-ACREB ob/ob littermates. Pointing to a direct role for CREB
in this process, we recovered the ATF3 promoter from immuno-
precipitates of CREB prepared from gonadal as well as subcuta-
neous adipose tissue by chromatin immunoprecipitation (ChIP)
analysis (Figure 5D).
We examined whether CREB inhibits adiponectin gene
expression in adipocytes through the induction of ATF3. Consis-
tent with this idea, ATF3 overexpression disrupted adiponectin
promoter activity in transient transfection assays with an adipo-
nectin-luciferase reporter (Figure 6A, top) (Kim et al., 2006).
Exposure of primary adipocytes to FSK also reduced adiponec-
tin mRNA amounts; these effects were suppressed when cells
were depleted of ATF3 using adenovirally encoded ATF3 RNAi
(Figure 6A, bottom). We also employed ATF3/ mice to deter-
mine whether ATF3 mediates the HFD-associated decrease in
adiponectin gene expression. In line with the upregulation of
ATF3 mRNA and protein, HFD feeding reduced adiponectin
gene expression inWAT fromWT littermates (Figure 6B). But adi-
ponectin mRNA amounts remained high in HFD-fed ATF3/
mice, demonstrating the importance of ATF3 in this setting.
Figure 4. Adiponectin Modulates Hepatic
Gluconeogenesis via AMPK-Mediated Phos-
phorylation of CRTC2
(A–D) Effect of adenoviral adiponectin (AdipoQ) or
green fluorescent protein (GFP) expression on
amounts of phospho-CRTC2 (A), CRE-luciferase
reporter activity (B), gluconeogenic gene expression
(C), and glucose secretion (D) from transduced
primary hepatocytes exposed to FSK (10 mM) and/or
insulin (100 nM). Coinfection with adenoviruses en-
coding WT or phosphorylation-defective (S171A)
CRTC2 are indicated. Data are means ± SEM; n = 3
per group.
(E–F) Phospho-CRTC2 amounts (E) and CRE-lucif-
erase reporter activity (F) in primary hepatocytes
exposed to increasing concentrations of adiponectin
protein (2–15 mg/ml). Ad-CRE luc activity was
measured in cells treated with FSK (10 mM) plus resis-
tin (15 mg/ml) for 5 hr. Representative of three indepen-
dent experiments shown. Data are means ± SEM;
n = 3.
In addition to its effects on adiponectin,
exposure to FSK also inhibited GLUT4
promoter activity; these effects were
reversed in cells expressing dominant-nega-
tive ACREB protein (Figure 6C). In keeping
with the presence of ATF3 binding sites at
508 and 555 on this promoter, exposure
to FSK increased ATF3 occupancy over the
GLUT4 gene. Correspondingly, ATF3 over-
expression reduced GLUT4-luciferase
reporter activity, while disruption of the
ATF3 gene increased GLUT4 mRNA and
protein amounts in WAT from ATF3/ mice (Figures 6C and
S11). Taken together, these results support the notion that the
CREB-mediated induction of ATF3 in obesity promotes insulin
resistance through the subsequent downregulation of adiponec-
tin and GLUT4 expression in adipose (Figure 6D).
DISCUSSION
Obesity triggers a number of perturbations that alter adipose
tissue homeostasis (de Luca and Olefsky, 2008; Lumeng et al.,
2007). Increases in adipose tissue mass promote local areas of
microhypoxia that activate stress and inflammatory pathways
within the adipocytes and surrounding stromal vascular cells.
The subsequent release of chemokines by adipocytes is thought
to cause a large and sustained influx of circulating monocytes
that become adipose tissue macrophages (ATMs). Because
they also release a variety of cytokines, ATMs further exacerbate
the chronic inflammatory state in adipose by promoting lipolysis
as well as insulin resistance in adipocytes (Xu et al., 2003). This
insulin-resistant state in adipose can then be communicated to
the periphery through increases in circulating FFAs and through
changes in the repertoire of secreted adipokines, culminating in
systemic insulin resistance in both liver and muscle.
We found that the activation of CREB in adipose represents an
important step in the development of insulin resistance inCell Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc. 281
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Transcriptional Repressor ATF3 in Adipose
under Obese Conditions
(A) Results from gene profiling studies showing genes
induced 2-fold or greater in primary adipocytes
following exposure to FSK and in WAT harvested
from HFD- relative to NC-fed mice. Presence of
conserved CREB binding site (CRE) and TATA box is
indicated.
(B) Top left, relative ATF3mRNA amounts inWAT from
lean and ob/obmice. Top right, effect of NC- andHFD-
feeding on ATF3 protein amounts in white adipose
from WT mice. Bottom shows relative ATF3 mRNA
(left) and protein (right) amounts in WAT from
F-ACREB ob/ob mice compared to control ob/ob
animals.
(C) Q-PCR analysis of ATF3 mRNA in HEK293T cells
(top) and in cultured primary adipocytes of ob/ob
mice (bottom) following exposure to forskolin. Effect
of ACREB expression, either acutely through adeno-
viral infection (ob Ad-ACREB) or chronically in cells
from ACREB transgenic mice (tg ob), is indicated.
(D) ChIP assay of subcutaneous or gonadal WAT
showing CREB occupancy over the ATF3 promoter
in vivo. CREB binding to positive control (FDPS) and
negative control (actin) promoters is shown for
comparison. Relative recovery of ATF3 promoter
from immunoprecipitates of CREB or nonspecific
IgG is also indicated. Position of CREB binding site
and TATA box relative to transcription start site on
the ATF3 promoter is shown.obesity. When CREB activity is inhibited, adipose tissue and
systemic insulin sensitivity are relatively preserved in obese
mice. Because the ACREB transgene is selectively expressed
in adipocytes, the systemic insulin-sensitive phenotype must
originate within adipose itself. Despite these improvements in
insulin sensitivity, F-ACREB animals gain weight comparably to
controls in the context of HFD feeding or in ob/ob mice, indi-
cating that obesity can be uncoupled from insulin resistance.
In parallel with the increases in adipose tissue insulin sensi-
tivity and glucose transport, pancreatic islet function is also rela-
tively preserved in F-ACREB mice. Although the underlying
mechanism is unclear, we imagine that the associated improve-
ments in glucose and lipid homeostasis may protect against
deterioration of beta cell function often associated with obesity.
Indeed, the systemic changes in F-ACREB mice are reminiscent
of those observed in fatty acid binding protein (FABP4, FABP5)
knockout mice, which remain insulin sensitive under obese
conditions (Cao et al., 2008). Despite comparable circulating
concentrations of free fatty acids, FABP4/;FABP5/
knockout mice were protected from hepatic steatosis due to
increases in circulating concentrations of the ‘‘lipokine’’
hormone palmitolineate. Further studies should reveal whether
the composition of circulating free fatty acids is similarly altered
in F-ACREB animals.
ATM content and inflammatory gene expression were also
reduced in F-ACREB mice, and these animals were protected
from the subsequent development of insulin resistance in the
other major insulin target tissues, muscle and liver. The secretion
of TNF by ATMs has been shown to increase adipocyte insulin
resistance through the activation of the Ser/Thr kinase JNK1,282 Cell Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc.which in turn phosphorylates the insulin receptor substrate 1
(IRS1) on serine (Sabio et al., 2008). These localized changes
in adipocyte insulin resistance are transmitted to the liver
through the release of interleukin 6 (IL-6) from adipocytes,
leading to hepatic upregulation of SOCS3, an inhibitor of insulin
receptor signaling. Although we did not observe changes in
circulating concentrations of IL-6 in F-ACREB relative to control
mice, it is interesting to note that the IL-6 promoter contains
a number of CREB binding sites that can potentially mediate
induction of this gene in response to cAMP signals (Zhang
et al., 2005b).
CREB was found to compromise adipocyte function in part by
stimulating the expression of ATF3, a repressor that binds to and
inhibits transcription of the adiponectin and GLUT4 genes. Sup-
porting this idea, ATF3 has been found to inhibit adiponectin
gene expression in 3T3-L1 adipocytes in response to ER stress
signals (Kim et al., 2006; Koh et al., 2007). Disrupting CREB
activity in adipocytes was sufficient to promote relatively normal
glucose homeostasis in the contexts of dietary and genetic
obesity. Indeed, modest overexpression of adiponectin or
GLUT4 in fat also appears to enhance glucose tolerance and
insulin sensitivity and, in the case of adiponectin, to reduce
inflammatory pathway signaling (Berg et al., 2001; Carvalho
et al., 2005; Combs et al., 2001; Kim et al., 2007; Satoh et al.,
2005; Yamauchi et al., 2002b).
In addition to its effects on ATF3, CREB may modulate the
expression of other cellular genes that influence lipidmetabolism
in adipocytes. For example, cAMP appears to increase mRNA
amounts for the inhibitor of DNA binding 2 (Id2), a helix-loop-
helix protein that has been found to promote adipogenesis by
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Role of CREB in ObesityFigure 6. ATF3Mediates Inhibitory Effects of CREB on
GLUT4 and Adiponectin Gene Expression in Adipose
under Obese Conditions
(A) Top left, transient assay showing adiponectin-luciferase
reporter activity in control and ATF3 overexpressing
HEK293T cells. At the top right, an immunoblot shows the
effect of adenovirally encoded ATF3 RNAi or control (USi)
RNAi on amounts of ATF3 protein in primary adipocytes.
Bottom showsQ-PCR analysis of adiponectin mRNA amounts
in primary adipocytes infected with adenovirally encoded
unspecific (USi) or ATF3 RNAi. Cells exposed to TNF-a or
FSK for 24 hr are indicated.
(B) Top, immunoblot of ATF3 protein amounts inWAT fromWT
and Atf3/ mice under NC and HFD conditions. Bottom
shows Q-PCR analysis of adiponectin and ATF3 mRNA
amounts in WAT from Atf3/ and control littermates main-
tained on NC or HFD.
(C) Top, transient assay of HEK293T cells showing effect of
A-CREB or ATF3 overexpression on GLUT4-luciferase
reporter activity in HEK293T cells under basal conditions
and following exposure to FSK for 4 hr. at bottom left,
a ChIP assay shows recovery of GLUT4 promoter from immu-
noprecipitates of ATF3 or nonspecific IgG prepared from
HEK293T cells following exposure to FSK as indicated.
Recovery of positive control (cyclin D1) or negative control
(actin) promoters in immunoprecipitates of ATF3 is included
for comparison. At bottom right, GLUT4 protein amounts in
white adipose from Atf3/ and WT littermates are shown.
(D) Adipocyte CREB promotes insulin resistance in obesity.
Under lean conditions, increases in circulating adiponectin
reduce hepatic glucose output during fasting by triggering
the AMPK-mediated phosphorylation of the CREB coactivator
CRTC2 in hepatocytes. Adipocyte CREB is activated in
obesity, where it promotes insulin resistance via the ATF3-
mediated inhibition of adiponectin and GLUT4 gene expres-
sion.stimulating the expression of PPARg in adipose (Park et al.,
2008). Indeed, adipocyte Id2 gene expression is increased in
obesity, while mice with a knockout of Id2 gene have reduced
adipose stores at birth. Based on the presence of conserved
CREB binding sites in the Id2 gene and the ability for cAMP to
stimulate Id2 gene expression, CREB may modulate the lipo-
genic program in adipocytes through upregulation of this tran-
scription factor.
Taken together, these results show that targeting therapies to
adipose tissue and, in particular, to the CREB signaling system
could have important therapeutic benefits in a variety of
insulin-resistant states. Further analysis of other adipocyte
genes that are modulated by CREB under obese conditions
should provide greater insight into this process.
EXPERIMENTAL PROCEDURES
Mice
A 5.6 kb fragment of the aP2 promoter and a 256 bp fragment encoding FLAG-
ACREB were subcloned into the pWhere vector containing two H19 chromatin
insulators (InvivoGen). F-ACREB transgenic mice were generated on the B6
and CB6 backgrounds. Mice were genotyped using the following primer
sets for ACREB transgene: F tg, GTCCAGTGATCATTGCCAGG; F WT,
TGCTGCCGCATCAGGCAAT; and R, AGCACTGCCACTCTGTTCTC (WT =
230 bp, tg = 380 bp). Ob/+ mice were purchased from Jackson Laboratory
and bred in the Salk transgenic facility. Transgenic mice were crossed toob/+ mice to obtain tg-ob/+ mice and WT-ob/+ mice. This intercross gener-
ated tg; ob/ob (tg-ob) and WT; ob/ob (WT-ob) mice. For HFD studies, 8-
week-old male mice were fed on 60% HFD for 12–24 weeks. ATF3/ mice
(Hartman et al., 2004) were maintained on 45% HFD or 12% NC diet for 12
weeks.
Cells and Reagents
HEK293T cells were maintained in DMEM supplemented with 10% FBS.
Adenoviruses encoding TORC2, GFP, Adiponectin, ATF3, ACREB, and
ATF3i were generated using the Ad-Track-pAdEasy system (Herzig et al.,
2001). Target sequence for ATF3 RNAi is AAGGAACATTGCAGAGCTAAG (nt
527–546). pGL3-Adiponectin-luc (Iwaki et al., 2003) contains 1 kb of the human
adiponectin promoter fused to luciferase cDNA. TNF-a (Calbiochem) and FSK
(Sigma) were used at 10 ng/ml (in PBS) and 10 mM (in DMSO), respectively.
Antibodies include adiponectin (Sigma; 1:8000), Atf3 (Santa Cruz; 1:500),
HSP90 (Santa Cruz; 1:5000), p-AMPK and AMPK, p-ACC and ACC, and
p-AKT and AKT (Cell Signaling) at 1:1000.
Adiponectin protein was collected in serum-free medium from primary
hepatocytes transduced with Ad-adiponectin virus. Multimeric forms of this
hormone were confirmed by SDS-PAGE under reducing and nonreducing
conditions (Pajvani et al., 2004). Adiponectin protein concentrations were
determined by ELISA assay (Linco Research, Inc.; St. Charles, MO).
Primary Hepatocyte Culture
Mouse hepatocytes were harvested, cultured, and infected with adenoviruses
as previously described (Dentin et al., 2004). For reporter studies, Ad-CRE luc-
infected primary hepatocytes were exposed to FSK for 5 hr, followed by expo-
sure to control medium or insulin for 3 hr. Luciferase activity was normalized to
b-gal activity from coinfected Ad-RSV b-gal vector. For glucose outputCell Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc. 283
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medium); glucose output was then collected for 1 hr in control medium supple-
mented with 10 mM lactate and 1 mM pyruvate. For studies with adiponectin
protein, active multimeric forms of adiponectin were confirmed by SDS-PAGE
analysis under nonreducing conditions.
Primary Adipocyte Culture and Glucose Uptake
Adipocytes were isolated from mouse visceral adipose tissue as described
(Karnieli et al., 1981), with the following modifications. Adipose tissue was
incubated for 30–45 min with Type I Collagenase (Invitrogen) in Ringer Bicar-
bonate-HEPES (KRBH) buffer (10 mM bicarbonate, 30 mM HEPES, 200 nM
adenosine, 2.5 mM glucose 1% fatty-acid-free BSA [pH 7.4]) at 37C. The
digestion mixture was filtered through a nylon strainer and centrifuged at
400 3 g. Adipocytes in the supernatant were resuspended in glucose-free
KRBH. Glucose uptake was measured using [3H]2-deoxyglucose. Cells were
pretreated with insulin for 20 min and incubated at 37C with 100 nM-labeled
deoxyglucose (4 mCi/ml) for 5 min. Labeled cells were collected after centrifu-
gation at 10,000 3 g for 10 s. Cells were counted directly by scintillation. Cell
aliquots were used to determine protein content and cell number for normali-
zation.
Euglycemic-Hyperinsulinemic Clamps
Mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine.
Clamp studies on catheterized mice were performed as described (Hevener
et al., 2003). HPLC-purified [3-3H]glucose (0.05 mCi/min, New England
Nuclear) was infused for 2 hr (basal infusion period) into 6 hr-fasted mice using
microdialysis pumps, and blood samples were collected from the tail vein.
Following the basal infusion period, a 120 min euglycemic-hyperinsulinemic
clamp period was initiated with a continuous infusion of human insulin (Humu-
lin R) at 12.5 mU/kg/min. Blood samples were collected at 10 min intervals for
the measurement of plasma glucose concentrations. A 50% glucose solution
was infused at variable rates to maintain euglycemia during the clamp. Plasma
was deproteinized with ZnSO4 and Ba(OH)2, dried to remove
3H2O, resus-
pended in H2O, and counted in scintillation fluid for detection of
3H.
RNA Analysis
RNA extractions were carried out using TRIzol followed by purification over
a QIAEASY RNA column. Reverse transcribed- and quantitative-PCR were
carried out as described. The primer sets for atf3: AAGACAGAGTGCCTGCA
GAA and GTGCCACCTCTGCTTAGCTC (232 bp); for nr4a2: CGCCGAAATC
GTTGTCAGTA and CGACCTCTCCGGCCTTTTA (101 bp); for adpn: AAG
GACAAGGCCGTTCTCTT and GAAAGCCAGTAAATGTAGAG (180 bp); for
pgc1a: CAAGTCTAACTATGCAGACC and ACTTGCTCTTGGTGGAAGCA (67
bp); for ucp2: GATGGCTTGGCAGTCAAGAA and GAACTCCTGGAACTCGAG
TTA (110 bp); for l32: TCTGGTGAAGCCCAAGATCG and CTCTGGGTTTCCG
CCAGTT (100 bp).
Blood Metabolites
Glucose, FFA, TG, and ketones were measured using OneTouch Ultra Gluc-
ometer, NEFAC (Wako Chemicals USA, 99475409), and Serum TGDetermina-
tion Kit (Sigma, TR0100), respectively. Insulin, glucagon, adiponectin, and re-
sistin were measured using kits from ALPCO (10115001 and 48-GLUCA-90)
and Linco Research, Inc. (EZMADP-60K and CYT292), respectively.
Chromatin Immunoprecipitation
ChIP in 293T cells and tissues was carried out as described (Koo et al., 2005).
Lysates were immunoprecipitated with antibodies to CREB (244) as well as
ATF3. Primers are as follows for atf3: CCGAACTTGCATCACCAGT and
CGTTGCATCACCCCTTTTAT, which produce a 198 bp band following ampli-
fication. Controls used in this experiment: positive control (fdps), GTAAGA
CAGGCAGCCAAAGC and CCACACTAAGGGCGGAAATA (267 bp); negative
control (actin), TGCTATCCCTGTACGCCTCT and CTCCTTAATGTCACG
CACGA (227 bp). Annealing temperature Tm = 56C.
Microarray
Total RNA samples were amplified, labeled, and hybridized to Affymetrix
Mouse Genome 430A 2.0 Arrays (Affymetrix; Santa Clara, CA) using standard
protocols. Scanned images were analyzed by using DChIP software. Lower284 Cell Metabolism 9, 277–286, March 4, 2009 ª2009 Elsevier Inc.bounds of the 90% confidence intervals of fold changes (LFC) were used to
identify cAMP-inducible genes. CRE site assignments have been described
(Zhang et al., 2005b) and appear on the website http://natural.salk.edu/
CREB. Microarray data have been deposited and can be accessed at NCBI
GEO (accession number: GSE14363).
Metabolism
Liver glycogen and ketones were determined as described (Qi et al., 2006).
Body temperature, food intake, metabolic cages, and histology were carried
out as reported (Qi et al., 2006). Effects of insulin on AKT phosphorylation in
muscle and liver were determined following administration of insulin i.p. at
0.75 U/kg body weight. Tissues were harvested 15 min after injection.
Statistical Analysis
Results are expressed as mean ± SEM. Comparisons between groups were
made by unpaired two-tailed Student’s t test. p < 0.05 was considered statis-
tically significant. All experiments were conducted on at least two independent
occasions.
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